Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-12-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于获得创新药《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a pharmaceutical company about receiving approval from the National Medical Products Administration for clinical trials of several innovative drugs. It includes detailed descriptions of the drugs, their intended uses, and clinical trial approval numbers. The document is relatively short (2203 characters) and serves as a regulatory announcement about a specific event (clinical trial approval). It does not contain financial data, management discussion, or detailed financial reports. It is not an annual or interim report, earnings release, or any other financial filing. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-12-16 Chinese
北京市中伦律师事务所关于海思科医药集团股份有限公司2025年度向特定对象发行A股股票的补充法律意见书（四）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's planned private placement of A shares in 2025. It includes extensive financial data, legal compliance checks, administrative penalties, and detailed descriptions of the company's fundraising use, especially for new drug R&D projects. The document references the issuance of shares to specific investors and discusses the legal and financial aspects of this capital raising activity. It is not a general annual or quarterly report, nor an earnings release or audit report. It is a legal opinion related to a capital raising event, specifically a private placement of shares. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2025-12-15 Chinese
信永中和会计师事务所关于海思科医药集团股份有限公司申请向特定对象发行股票的审核问询函之回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed response report from a pharmaceutical company (海思科医药集团股份有限公司) addressing an inquiry from the Shenzhen Stock Exchange regarding its application for a private placement of shares. The content includes extensive financial data, product revenue breakdowns, government subsidies, production capacity utilization, and explanations of financial trends and accounting policies. It is a comprehensive report with substantive financial analysis and explanations related to a capital raising activity (private placement of shares). The document is lengthy (15,000 characters) and contains detailed financial and operational data, not merely an announcement or a certification. The key focus is on the company's financial and operational status in the context of a capital issuance application, which aligns with a Capital/Financing Update filing. Therefore, the document should be classified as a Capital/Financing Update (CAP).
2025-12-15 Chinese
关于向特定对象发行股票的审核问询函回复（修订稿）更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the company's response to a regulatory inquiry from the Shenzhen Stock Exchange about a proposed private placement of shares. It references updates to application documents and financial data up to the 2025 half-year period but does not contain the actual financial statements or detailed financial analysis itself. The document is relatively short (812 characters) and serves as an update on the status of the company's application and regulatory review process. It is not a full financial report, earnings release, or detailed investor presentation. It is an announcement related to capital raising activities (private placement of shares) and regulatory review. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-12-15 Chinese
中信证券股份有限公司关于海思科医药集团股份有限公司申请向特定对象发行股票的审核问询函之回复报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to a regulatory inquiry from the Shenzhen Stock Exchange regarding a company's application for a specific share issuance. It contains extensive financial data, operational analysis, product market information, government subsidies, and detailed explanations of revenue and profit trends over multiple years. The document includes comprehensive financial figures, business performance analysis, and regulatory compliance information. It is not a brief announcement or a certification letter but a substantive report with financial and operational details. The content aligns with a Capital/Financing Update (CAP) as it relates to a specific share issuance application and includes detailed financial and operational disclosures to support the issuance. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2025-12-15 Chinese
关于1类创新药被纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company Haise Medical Group regarding the inclusion of two innovative drugs into the National Medical Insurance Directory (2025 edition). It provides details about the drugs, their indications, classification codes, and the effective period of the insurance agreement. The document also includes a risk warning about the impact on the company's short-term operating results. The document length is short (1253 characters) and it is an announcement of a regulatory or business update rather than a financial report or detailed presentation. It does not contain financial statements, earnings data, or management discussion. It is not a report publication announcement since it contains substantive content about the insurance inclusion. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about business developments and compliance with national insurance policies.
2025-12-08 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.